France France is rediscovering its mojo. After a period of relative stagnation, the country’s highly strategic USD 65 billion healthcare and life sciences market is once again an attractive investment proposition. With Brexit uncertainties across the channel and populist tendencies souring the prospects of some of its neighbours, France – under…
Korea Min-Young Kim, general manager at Ipsen Korea discusses her strategy to refocus the Korean affiliate away from the toxin market and towards oncology and rare diseases. She also documents Ipsen’s rapid local growth and increasing market share. Miss Kim also gives her assessment of the current drug pricing situation, as…
Ipsen Following on from Johnson & Johnson’s acquisition of Actelion in January 2017 and Takeda’s takeover of Shire two years later, pharma multinationals’ rush to snap up rare disease specialists continues with Ipsen’s proposed acquisition of Clementia Pharmaceuticals. Industry insiders predict that this trend is set to continue well into the…
China This is the first in a series of articles examining what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. We start in China, where the heads of Merck, Ipsen, Chiesi, Gedeon Richter and AbbVie’s Chinese affiliates give their…
Algeria Adlane Soudani, general manager of Ipsen’s Algerian affiliate, lifts the lid on Ipsen’s ambitions for the local market, and the company’s parallel strategies to ramp up local production while simultaneously delivering tech transfer to local partners. Our rather distinctive approach is to deploy parallel strategies: we will maintain our…
Algeria Ipsen’s Guillaume Freneuil gives his take on the importance of the Algerian market to the global group. If we are investing right now in Algeria it is because we envisage further growth here to be able to serve patient needs 33 percent of Sales within Ipsen are now in…
Turkey Bucking a global trend for increased focus on outpatient and preventative care, Turkey is doubling down on hospital investment. Throughout many of the healthcare systems in North America and Europe, there is an increasing emphasis on outpatient and preventative care. In terms of health economics, governments see a great benefit in…
Turkey Ozlem Fidanci, CEO of the Middle East and Turkey at Philips, shares the collaborative approach Philips has implemented in Turkey and its successes, provides insights into future collaborations and discusses the importance of a holistic approach focusing on preventive technologies. Having a holistic approach across healthy living, prevention, diagnostic,…
Spain Alfonso Beltrán García-Echániz, director of the Spanish Foundation for Innovation and Prospective Health (FIPSE), highlights the foundation’s focus, as a new instrument to foster innovation in Spain, as well as shares his expert insights on the future of innovation in the country. The focus of our work is to…
Spain Javier Alvarado, general manager of Mundipharma Spain, discusses his current priorities and the innovation the company is bringing to the market through a diversified portfolio. Furthermore, he points out the importance of long-term strategic partnerships for the company´s success and his future aspirations for the affiliate. Of course, none…
China Alan Chen, general manager for Ipsen China, shares the exciting journey of Ipsen in China in the past few years as the third-largest affiliate for the group globally, upcoming innovative product launches, the reorganization and HR strategy he has headed to take Ipsen China to the next stage of its…
Algeria Moncef Meklati, Merck’s general manager for North West Africa, discusses the company’s ambitions in the region, the key to successful joint ventures and evolving attitudes to chronic diseases in Algeria. From the first day I started working for Merck, I’ve been impressed by the strong commitment of my team…
See our Cookie Privacy Policy Here
